Mark Andrew Lemmon FRS[2] (born 1964) an English-born biochemist, is the Alfred Gilman Professor and Department Chair of Pharmacology at Yale University where he also directs the Cancer Biology Institute.

[5] He was educated at Norwich School (from 1976 to 1983), and then at Hertford College, Oxford, from which he graduated with a first class Bachelor of Arts (BA) degree in biochemistry in 1988.

[4] He completed his PhD at Yale University as a Howard Hughes Medical Institute Predoctoral Fellow supervised by Donald Engelman[6] for research on the oligomerization of transmembrane α-helices.

Lemmon has made important contributions to the discovery of both normal and pathological activation mechanisms of growth factor receptors and the signalling networks that they engage within cells.

[2] Before moving to Yale, Lemmon was George W. Raiziss Professor and Chair of Biochemistry and Biophysics in the Perelman School of Medicine at the University of Pennsylvania.